$XBI $127 +4%
Pipeline Updates
$CRMD -22% Plan is to be able to resubmit the defend cap NDA in the fourth quarter of 2021. source
$APLS +7% (AH) FDA approves new treatment for adults with serious rare blood disease. source
$RGNX +2% REGENXBIO PRESENTS ADDITIONAL POSITIVE INTERIM DATA FROM PHASE I/II TRIAL OF RGX-121 FOR THE TREATMENT OF MPS II (HUNTER SYNDROME) AT AMERICAN SOCIETY OF GENE AND CELL THERAPY'S 24TH ANNUAL MEETING. source
Posted by DV
Comments